Flexion Therapeutics Inc FLXN Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125

16:24 EDT 12 Oct 2018 | BioPortfolio Reports

Flexion Therapeutics Inc FLXN Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Flexion Therapeutics Inc Flexion develops and commercializes pain therapies. The company's pipeline is focused on indications that includes osteoarthritis knee pain repeat administration, osteoarthritis knee synovial inflammation, bilateral knee osteoarthritis pain shoulder and hip osteoarthritis pain and inflammatory conditions. The company's marketed product includes Zilretta which is the first and only extendedrelease, intraarticular therapy for patients confronting osteoarthritisrelated knee pain. Flexion employs its proprietary microsphere technology to combine TA with a PLGA matrix for formulating Zilretta. It offers antiinflammatory and analgesic therapies for osteoarthritis. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc Key Recent Developments

Aug 07,2018: Flexion Therapeutics reports secondquarter 2018 financial results and recent business highlights

Jun 21,2018: Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for the Second Year in a Row

May 08,2018: Flexion Therapeutics Reports FirstQuarter 2018 Financial Results and Recent Business Highlights

May 07,2018: Flexion Therapeutics Appoints David Arkowitz As Chief Financial Officer

Mar 08,2018: Flexion Therapeutics Reports Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Flexion Therapeutics Inc FLXN Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125


More From BioPortfolio on "Flexion Therapeutics Inc FLXN Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125"

Quick Search


Relevant Topics

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...